Refractory/Relapsed AML - Why and How to Treat?

Updates on the FLT3 inhibitor FF-10101 for the treatment of R/R AMLПодробнее

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AMLПодробнее

New Drugs: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with Susceptible IDH1 Mut...Подробнее

FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid LeukemiaПодробнее

Management of Relapsed Refractory AML with FLT3 +ve mutation – Dr. Ahmad Alotaibi (May 26-27, 2023)Подробнее

Allogenic Transplantation in Relapsed Refractory AML & Maintenance -Dr. Ahmad Alotaibi(Jun 3-4' 22)Подробнее

What time is the right time for transplantation?Подробнее

How to treat relapsed acute myeloid leukaemiaПодробнее

Advances in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (AML)Подробнее

Menin inhibition in relapsed/refractory AML: what do the data tell us?Подробнее

Treatment Options for Relapsed or Refractory AML: IDH1, IDH2, and FLT3 - Blood Cancer OncTalkПодробнее

What are the newest, most promising drugs for relapsed/refractory AML? #AMLПодробнее

What's the difference between relapse and refractory AML? #AML #leukemia #cancer #AMLПодробнее

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid LeukemiaПодробнее

Menin inhibition in relapsed/refractory AML: what do the data tell us?Подробнее

ASH 2022: Relapsed/Refractory AML - Results from the Randomized Phase III ASAP TrialПодробнее

IDH inhibitors in relapsed/refractory AMLПодробнее

Evolving landscape in management of Relapsed Refractory AML - Syed Osman (RUH) - 11-12 Feb2022Подробнее

What new treatments are there for relapsed acute myeloid leukemia?Подробнее

What are the latest advances in treatment failure and relapse in AML?Подробнее